The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 746-754

  Wozniak, Krystyna M ^a,b   Wu, Ying ^a,b   Vornov, James J ^c   Lapidus, Rena ^b,d   Rais, Rana ^a   Rojas, Camilo ^a,b   Tsukamoto, Takashi ^a,b   Slusher, Barbara S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EISAI INC   (United States)

^c PAREXEL INTERNATIONAL   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 2 MERCAPTOETHYL)BIPHENYL 2,3 DICARBOXYLIC ACID; E 2072; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; NEUROPROTECTIVE AGENT; OXALIPLATIN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG STRUCTURE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CONDUCTION; NERVE CONDUCTION DISORDER; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; THERMAL HYPERALGESIA;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOATES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HYPERALGESIA; LEUKEMIA L1210; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MOLECULAR STRUCTURE; NEURAL CONDUCTION; NEURALGIA; ORGANOPLATINUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NEUROPATHY; SULFHYDRYL COMPOUNDS; TISSUE DISTRIBUTION;

EID: 84869215781     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.197665     Document Type: Article

References (62)

1. Adedoyin MO, Vicini S, and Neale JH (2010) Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Mol Pain 6:60.
2. Bařinka C, Rojas C, Slusher B, and Pomper M (2012) Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 19:856-870.
3. Bennett GJ and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107.
4. Bergeron R, Coyle JT, Tsai G, and Greene RW (2005) NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30:7-16. (Pubitemid 40024394)
5. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, and Nicoletti F (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor- . J Neurosci 18:9594-9600. (Pubitemid 28543740)
6. Cangro CB, Namboodiri MA, Sklar LA, Corigliano-Murphy A, and Neale JH (1987) Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J Neurochem 49:1579-1588. (Pubitemid 17161382)
7. Carlton SM, Hargett GL, and Coggeshall RE (2001) Localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. Neuroscience 105:957-969. (Pubitemid 32786809)
8. Carozzi VA, Canta A, Oggioni N, Ceresa C, Marmiroli P, Konvalinka J, Zoia C, Bossi M, Ferrarese C, Tredici G, et al. (2008) Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. J Anat 213:539-546.
9. Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, Wozniak KM, and Cavaletti G (2010) Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 17:380-391.
10. Carpenter KJ, Sen S, Matthews EA, Flatters SL, Wozniak KM, Slusher BS, and Dickenson AH (2003) Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. Neuropeptides 37:298-306. (Pubitemid 37464033)
11. Cavaletti G and Marmiroli P (2004) Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf 3:535-546. (Pubitemid 39530207)
12. Chen SR, Wozniak KM, Slusher BS, and Pan HL (2002) Effect of 2-(phosphono-methyl)- pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 300:662-667.
13. Coyle JT (1997) The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis 4:231-238.
14. Coyle JT and Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695. (Pubitemid 23350687)
15. Drummer OH and Jarrott B (1984) Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. Biochem Pharmacol 33:3567-3571.
16. Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A 100:9554-9559. (Pubitemid 37033966)
17. Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, and Kleinman JE (2004) Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29:117-125. (Pubitemid 38068021)
18. Gill JS and Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842-2850. (Pubitemid 28294593)
19. Giustarini D, Dalle-Donne I, Milzani A, and Rossi R (2011) Detection of glutathione in whole blood after stabilization with N -ethylmaleimide. Anal Biochem 415:81-83.
20. Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP, and Pomper MG (2008) Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res 99:324-332.
21. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
22. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
23. Jackson PF, Tays KL, Maclin KM, Ko YS, Li W, Vitharana D, Tsukamoto T, Stoermer D, Lu XC, Wozniak K, et al. (2001) Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem 44:4170-4175. (Pubitemid 33095323)
24. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B, and Neale JH (2004) Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 47:1729-1738. (Pubitemid 38380916)
25. Kuner R (2010) Central mechanisms of pathological pain. Nat Med 16:1258-1266.
26. Lau A and Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460:525-542.
27. Long JB, Yourick DL, Slusher BS, Robinson MB, and Meyerhoff JL (2005) Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol 508:115-122. (Pubitemid 40169909)
28. Losi G, Vicini S, and Neale J (2004) NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 46:490-496. (Pubitemid 38224434)
29. Majer P, Hin B, Stoermer D, Adams J, Xu W, Duvall BR, Delahanty G, Liu Q, Stathis MJ, Wozniak KM, et al. (2006) Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1 side chain. J Med Chem 49:2876-2885.
30. Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Poláková J, Shaffer KA, et al. (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 46:1989-1996. (Pubitemid 36532241)
31. Meyerhoff JL, Carter RE, Yourick DL, Slusher BS, and Coyle JT (1992) Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. Brain Res 593:140-143.
32. Nagel J, Belozertseva I, Greco S, Kashkin V, Malyshkin A, Jirgensons A, Shekunova E, Eilbacher B, Bespalov A, and Danysz W (2006) Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain-relation to brain concentration. Neuropharmacology 51:1163-1171. (Pubitemid 44715967)
33. Neale JH, Olszewski RT, Gehl LM, Wroblewska B, and Bzdega T (2005) The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 26:477-484. (Pubitemid 41207880)
34. Neale JH, Olszewski RT, Zuo D, Janczura KJ, Profaci CP, Lavin KM, Madore JC, and Bzdega T (2011) Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 118:490-498.
35. Neugebauer V, Li W, Bird GC, and Han JS (2004) The amygdala and persistent pain. Neuroscientist 10:221-234. (Pubitemid 38678530)
36. Pacheco Otalora LF, Moffett JR, and Garrido-Sanabria ER (2007) Selective vulnerability of hippocampal NAAGergic neurons in experimental temporal lobe epilepsy. Brain Res 1144:219-230. (Pubitemid 46440851)
37. Passani LA, Vonsattel JP, Carter RE, and Coyle JT (1997) N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated -linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol Chem Neuropathol 31:97-118.
38. Pilkington AE and Waring RH (1988) The metabolism and disposition of D-penicillamine in the DA-strain rat. Eur J Drug Metab Pharmacokinet 13:99-104.
39. Plaitakis A and Constantakakis E (1993) Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res Bull 30:381-386. (Pubitemid 23072747)
40. Profaci CP, Krolikowski KA, Olszewski RT, and Neale JH (2011) Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology (Berl) 216:235-243.
41. Rais R, Hoover R, Wozniak K, Rudek M, Tsukamoto T, Alt J, Rojas C, and Slusher BS (2012) Reversible disulfide formation of the GCP-II inhibitor E2072 results in prolonged systemic exposures in vivo. Drug Metab Dispos http://dx.doi.org/10.1124/dmd.112.046821.
42. Robinson MB, Blakely RD, Couto R, and Coyle JT (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated -linked acidic dipeptidase activity from rat brain. J Biol Chem 262:14498-14506. (Pubitemid 17157357)
43. Rojas C, Frazier ST, Flanary J, and Slusher BS (2002) Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem 310:50-54. (Pubitemid 35387330)
44. Skipper HE, Schabel FM Jr, Wilcox WS, Laster WR Jr, Trader MW, and Thompson SA (1965) Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. Cancer Chemother Rep 47:41-64.
45. Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS, and Coyle JT (1990) Rat brain N-acetylated -linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 265:21297-21301. (Pubitemid 120014152)
46. Slusher BS, Tsai G, Yoo G, and Coyle JT (1992) Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated -linked acidic dipeptidase (NAALADase). J Comp Neurol 315:217-229.
47. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5:1396-1402.
48. Stoermer D, Vitharana D, Hin N, Delahanty G, Duvall B, Ferraris DV, Grella BS, Hoover R, Rojas C, Shanholtz MK, et al. (2012) Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds. J Med Chem 55:5922-5932.
49. Thomas AG, Liu W, Olkowski JL, Tang Z, Lin Q, Lu XC, and Slusher BS (2001) Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF- . Eur J Pharmacol 430:33-40. (Pubitemid 33042708)
50. Tsai GC, Stauch-Slusher B, Sim L, Hedreen JC, Rothstein JD, Kuncl R, and Coyle JT (1991) Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res 556:151-156.
51. Tsukamoto T, Wozniak KM, and Slusher BS (2007) Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 12:767-776. (Pubitemid 47362787)
52. Weng HR, Aravindan N, Cata JP, Chen JH, Shaw AD, and Dougherty PM (2005) Spinal glial glutamate transporters downregulate in rats with taxol-induced hyperalgesia. Neurosci Lett 386:18-22. (Pubitemid 41019636)
53. Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, et al. (2011) Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71:3952-3962.
54. Wozniak KM, Rojas C, Wu Y, and Slusher BS (2012) The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Curr Med Chem 19:1323-1334.
55. Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, and Neale JH (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69:174-181. (Pubitemid 27274170)
56. Yamamoto T, Hirasawa S, Wroblewska B, Grajkowska E, Zhou J, Kozikowski A, Wroblewski J, and Neale JH (2004) Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 20:483-494. (Pubitemid 38969633)
57. Yamamoto T, Kozikowski A, Zhou J, and Neale JH (2008) Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain 4:31.
58. Yamamoto T, Nozaki-Taguchi N, and Sakashita Y (2001) Spinal N-acetyl-α-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 909:138-144. (Pubitemid 32710127)
59. Yamamoto T, Saito O, Aoe T, Bartolozzi A, Sarva J, Zhou J, Kozikowski A, Wroblewska B, Bzdega T, and Neale JH (2007) Local administration of Nacetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur J Neurosci 25:147-158. (Pubitemid 46098894)
60. Zhang W, Murakawa Y, Wozniak KM, Slusher B, and Sima AA (2006) The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 247:217-223. (Pubitemid 44301265)
61. Zhang W, Slusher B, Murakawa Y, Wozniak KM, Tsukamoto T, Jackson PF, and Sima AA (2002) GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 194:21-28. (Pubitemid 34051551)
62. Zuo D, Bzdega T, Olszewski RT, Moffett JR, and Neale JH (2012) Effects of Nacetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. J Biol Chem 287:21773-21782.